Prognostic Value of MCM2 Immunoreactivity in Stage T1 Transitional Cell Carcinoma of the Bladder

Abstract
Objective:Due to the heterogeneous biologic behavior of stage T1 bladder carcinomas,there is a need for new markers allowing to assess the prognosis more accurately.To our knowledge,there are no reports on studies investigating minichromosome maintenance protein 2(MCM2)expression in bladder carcinomas.Thus,we investigated the prognostic value of MCM2 immunoreactivity in stage T1 bladder tumors.